Cure My Disease

Don't miss your cure!

 Log in / Sign up

Healthy volunteers help compare two forms of experimental drug

NCT ID NCT07331194

Completed Knowledge-focused Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study enrolled 54 healthy Chinese adults to compare two different tablet formulations of the experimental drug HMPL-523. Participants received a single 300 mg dose of each version in random order, and researchers measured drug levels in the blood to see if the formulations are bioequivalent. The goal is to ensure the modified tablet behaves the same as the original, supporting its use in future trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HMPL-523 acetate
What this could lead to
If the two formulations are shown to be bioequivalent, the modified tablet can be used in future studies with confidence that it works the same as the original.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual treatment effects. The results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shandong, 250014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.